Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | THRA | P10827 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27329952 | 0.95 | FOLH1 (0.46) | FOLH1FFAR4FFAR1APPPOLB | |
| SCHEMBL24217610 | 0.90 | FOLH1 (0.46) | FOLH1FFAR4POLBCA1CA2 | |
| SCHEMBL22878071 | 0.85 | FOLH1 (0.45) | FOLH1FFAR4FFAR1POLBCA1 | |
| SCHEMBL1404313 | 0.81 | FOLH1 (0.56) | FOLH1FFAR4FFAR1CA1CA2 | |
| SCHEMBL27303602 | 0.78 | FOLH1 (0.52) | FOLH1FFAR4FFAR1POLBCA1 | |
| SCHEMBL25741233 | 0.78 | FOLH1 (0.52) | FOLH1FFAR4FFAR1POLBCA1 | |
| SCHEMBL22131080 | 0.76 | FOLH1 (0.52) | FOLH1 | |
| SCHEMBL25801389 | 0.76 | FOLH1 (0.52) | FOLH1FFAR4FFAR1POLBCA1 | |
| SCHEMBL25573716 | 0.75 | FOLH1 (0.48) | FOLH1FFAR1POLBCA1CA2 | |
| SCHEMBL18811743 | 0.75 | FOLH1 (0.56) | FOLH1FFAR4CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | FOLH1 335/4885FFAR4 417/4885FFAR1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.